Handbook of experimental pharmacology最新文献_第4页

Adrenal Anion Channels: New Roles in Zona Glomerulosa Physiology and in the Pathophysiology of Primary Aldosteronism. 肾上腺阴离子通道：肾小球生理学和原发性醛固酮增多症病理生理学中的新角色。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_680

Gabriel Stölting, Ute I Scholl

引用次数: 0

β-Adrenoceptors in Cancer: Old Players and New Perspectives. 癌症中的β-肾上腺素受体:老玩家和新视角。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_701

Rosario Amato, Martina Lucchesi, Silvia Marracci, Luca Filippi, Massimo Dal Monte

{"title":"β-Adrenoceptors in Cancer: Old Players and New Perspectives.","authors":"Rosario Amato, Martina Lucchesi, Silvia Marracci, Luca Filippi, Massimo Dal Monte","doi":"10.1007/164_2023_701","DOIUrl":"10.1007/164_2023_701","url":null,"abstract":"Distress, or negative stress, is known to considerably increase the incidence of several diseases, including cancer. There is indeed evidence from pre-clinical models that distress causes a catecholaminergic overdrive that, mainly through the activation of β-adrenoceptors (β-ARs), results in cancer cell growth and cancer progression. In addition, clinical studies have evidenced a role of negative stress in cancer progression. Moreover, plenty of data demonstrates that β-blockers have positive effects in reducing the pro-tumorigenic activity of catecholamines, correlating with better outcomes in some type of cancers as evidenced by several clinical trials. Among β-ARs, β2-AR seems to be the main β-AR subtype involved in tumor development and progression. However, there are data indicating that also β1-AR and β3-AR may be involved in certain tumors. In this chapter, we will review current knowledge on the role of the three β-AR isoforms in carcinogenesis as well as in cancer growth and progression, with particular emphasis on recent studies that are opening new avenues in the use of β-ARs as therapeutic targets in treating tumors.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"665-688"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asthma and COPD: A Focus on β-Agonists - Past, Present and Future. 哮喘和慢性阻塞性肺病：关注β-兴奋剂--过去、现在和未来。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_679

Jillian G Baker, Dominick E Shaw

{"title":"Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.","authors":"Jillian G Baker, Dominick E Shaw","doi":"10.1007/164_2023_679","DOIUrl":"10.1007/164_2023_679","url":null,"abstract":"Asthma has been recognised as a respiratory disorder for millennia and the focus of targeted drug development for the last 120 years. Asthma is one of the most common chronic non-communicable diseases worldwide. Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide, is caused by exposure to tobacco smoke and other noxious particles and exerts a substantial economic and social burden. This chapter reviews the development of the treatments of asthma and COPD particularly focussing on the β-agonists, from the isolation of adrenaline, through the development of generations of short- and long-acting β-agonists. It reviews asthma death epidemics, considers the intrinsic efficacy of clinical compounds, and charts the improvement in selectivity and duration of action that has led to our current medications. Important β2-agonist compounds no longer used are considered, including some with additional properties, and how the different pharmacological properties of current β2-agonists underpin their different places in treatment guidelines. Finally, it concludes with a look forward to future developments that could improve the β-agonists still further, including extending their availability to areas of the world with less readily accessible healthcare.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"369-451"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10244604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Legal Framework for Public-Private Partnerships in Drug R&D. 药物研发中公私合作的法律框架》。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2024_728

Thomas Hirse

引用次数: 0

Novel and Proven Models of Public, Private, and Public-Private Partnerships in Healthcare: An Update. 医疗保健领域公私合作的新颖和成熟模式：最新进展。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2024_724

Heike A Wieland, Jochen Maas

引用次数: 0

Knowledge-Based Design of Multifunctional Polymeric Nanoparticles. 基于知识的多功能聚合物纳米颗粒设计。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_649

Mira Behnke, Caroline T Holick, Antje Vollrath, Stephanie Schubert, Ulrich S Schubert

{"title":"Knowledge-Based Design of Multifunctional Polymeric Nanoparticles.","authors":"Mira Behnke, Caroline T Holick, Antje Vollrath, Stephanie Schubert, Ulrich S Schubert","doi":"10.1007/164_2023_649","DOIUrl":"10.1007/164_2023_649","url":null,"abstract":"Conventional drug delivery systems (DDS) today still face several drawbacks and obstacles. High total doses of active pharmaceutical ingredients (API) are often difficult or impossible to deliver due to poor solubility of the API or undesired clearance from the body caused by strong interactions with plasma proteins. In addition, high doses lead to a high overall body burden, in particular if they cannot be delivered specifically to the target site. Therefore, modern DDS must not only be able to deliver a dose into the body, but should also overcome the hurdles mentioned above as examples. One of these promising devices are polymeric nanoparticles, which can encapsulate a wide range of APIs despite having different physicochemical properties. Most importantly, polymeric nanoparticles are tunable to obtain tailored systems for each application. This can already be achieved via the starting material, the polymer, by incorporating, e.g., functional groups. This enables the particle properties to be influenced not only specifically in terms of their interactions with APIs, but also in terms of their general properties such as size, degradability, and surface properties. In particular, the combination of size, shape, and surface modification allows polymeric nanoparticles to be used not only as a simple drug delivery device, but also to achieve targeting. This chapter discusses to what extent polymers can be designed to form defined nanoparticles and how their properties affect their performance.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"3-26"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9302619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Use of Adrenergic Receptor Ligands in Acute Care Settings. 肾上腺素能受体配体在急症护理中的临床应用。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_705

Erica Langnas, Mervyn Maze

引用次数: 0

Project-Based Public-Private Collaborations. 基于项目的公私合作。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2024_722

Peter Hein, Martin C Michel

{"title":"Project-Based Public-Private Collaborations.","authors":"Peter Hein, Martin C Michel","doi":"10.1007/164_2024_722","DOIUrl":"10.1007/164_2024_722","url":null,"abstract":"Project-based collaborations between a single academic group and a single pharmaceutical company arguably are the most frequent form of public-private partnership in preclinical research and development of new drugs. This chapter discusses the benefits of such collaborations for both sides and potential challenges that can arise before and during the conduct of a project. This is largely based on a survey of expectations and experience by 134 academic investigators with a history of engagement in a project-based collaboration with a pharmaceutical company as well as unstructured experience directly, and learned through discussions with colleagues, from the authors. Obviously, a key benefit for both sides is achieving goals that neither could easily achieve by itself. Scientific discovery, and publications, may be a shared benefit, while for academics, funding and access to compounds, and for industry, access to assay technology and reputational factors may be important. Major hurdles can be freedom to publish and assignment of intellectual property rights. On pragmatic grounds, reaching a contract can be cumbersome, which is largely attributable to the legal expectations and needs of both parties. However, overall satisfaction with project-based collaborations appears very high for academic investigators.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"21-31"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacology of Compounds Targeting Cation-Chloride Cotransporter Physiology. 针对阳离子-氯离子共转运体生理学的化合物药理学。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_692

Eric Delpire, Andrew S Terker, Kenneth B Gagnon

{"title":"Pharmacology of Compounds Targeting Cation-Chloride Cotransporter Physiology.","authors":"Eric Delpire, Andrew S Terker, Kenneth B Gagnon","doi":"10.1007/164_2023_692","DOIUrl":"10.1007/164_2023_692","url":null,"abstract":"Transporters of the solute carrier family 12 (SLC12) carry inorganic cations such as Na+ and/or K+ alongside Cl across the plasma membrane of cells. These tightly coupled, electroneutral, transporters are expressed in almost all tissues/organs in the body where they fulfil many critical functions. The family includes two key transporters participating in salt reabsorption in the kidney: the Na-K-2Cl cotransporter-2 (NKCC2), expressed in the loop of Henle, and the Na-Cl cotransporter (NCC), expressed in the distal convoluted tubule. NCC and NKCC2 are the targets of thiazides and \"loop\" diuretics, respectively, drugs that are widely used in clinical medicine to treat hypertension and edema. Bumetanide, in addition to its effect as a loop diuretic, has recently received increasing attention as a possible therapeutic agent for neurodevelopmental disorders. This chapter also describes how over the past two decades, the pharmacology of Na+ independent transporters has expanded significantly to provide novel tools for research. This work has indeed led to the identification of compounds that are 100-fold to 1000-fold more potent than furosemide, the first described inhibitor of K-Cl cotransport, and identified compounds that possibly directly stimulate the function of the K-Cl cotransporter. Finally, the recent cryo-electron microscopy revolution has begun providing answers as to where and how pharmacological agents bind to and affect the function of the transporters.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"249-284"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9977247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance. 眼睛中的肾上腺素受体--生理和病理生理学意义。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_702

Yue Ruan, Francesco Buonfiglio, Adrian Gericke

{"title":"Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance.","authors":"Yue Ruan, Francesco Buonfiglio, Adrian Gericke","doi":"10.1007/164_2023_702","DOIUrl":"10.1007/164_2023_702","url":null,"abstract":"The autonomic nervous system plays a crucial role in the innervation of the eye. Consequently, it comes as no surprise that catecholamines and their corresponding receptors have been extensively studied and characterized in numerous ocular structures, including the cornea, conjunctiva, lacrimal gland, trabecular meshwork, uvea, and retina. These investigations have unveiled substantial clinical implications, particularly in the context of treating glaucoma, a progressive neurodegenerative disorder responsible for irreversible vision loss on a global scale. The primary therapeutic approaches for glaucoma frequently involve the modulation of α1-, α2-, and β-adrenoceptors, making them pivotal targets. In this chapter, we offer a comprehensive overview of the expression, distribution, and functional roles of adrenoceptors within various components of the eye and its associated structures. Additionally, we delve into the pivotal role of adrenoceptors in the pathophysiology of glaucoma. Furthermore, we provide a concise historical perspective on adrenoceptor research, examine the distinct contributions of individual adrenoceptor subtypes to the treatment of various ocular conditions, and propose potential future avenues of exploration in this field.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"453-505"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138802871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0